MedTrace Logo

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

NCT05109949 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2021-11-19

No results posted yet for this study

Summary

To date one of the main independent biomarkers of cardiovascular disease is the arterial stiffness parameters measured by carotid-femoral pulse wave velocity. It is known that SGLT2 inhibitors develop cardiac protection over long term administration, but there's not enough studies about acute effects in early administration.

Conditions

  • Diabetes Mellitus Type 2 Without Complication

Interventions

DRUG

Dapagliflozin 10Mg Tab

Daily morning dose per oral of Dapagliflozin 10 mg for 7 days

DRUG

Empagliflozin 25 MG

Daily morning dose per oral of Empagliflozine 25 mg for 7 days

OTHER

Placebo

Daily morning dose per oral of Calcined magnesite 500 mg for 7 days

Sponsors & Collaborators

  • Centro Universitario de Ciencias de la Salud, Mexico

    lead OTHER

Principal Investigators

  • Fernando Grover-Páez, PhD · Institute of Experimental and Clinical Therapeutics (INTEC), CUCS

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-30
Primary Completion
2022-06-01
Completion
2022-08-01

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05109949 on ClinicalTrials.gov